Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

NCT05728541 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Tumors

Interventions

DRUG: SYH2043

Sponsor

CSPC Ouyi Pharmaceutical Co., Ltd.